论文部分内容阅读
目的:研究乙型肝炎肝衰竭应用恩替卡韦治疗的安全性和有效性。方法:选取我院于2012年1月-2015年1月期间就诊的乙肝肝衰竭患者60例,根据入院先后顺序分为两组:对照组(n=30)接受常规综合治疗,观察组(n=30)在常规综合治疗的基础上配合恩替卡韦治疗,对比两组的临床疗效。结果:观察组的1年生存率为76.67%,较对照组的46.67%明显提高(P<0.05);治疗后2组的ALB均明显提高,且观察组明显高于对照组(P<0.05);治疗后2组ALT与TBIL均明显降低,且观察组明显低于对照组(P<0.05)。结论:恩替卡韦辅助治疗乙肝肝衰竭能够提高患者的生存率、改善或维持患者的肝功能,且副反应少,是一种安全可靠的药物,值得临床推广。
Objective: To study the safety and efficacy of entecavir in the treatment of hepatitis B failure. Methods: Sixty patients with hepatitis B liver failure who were treated in our hospital from January 2012 to January 2015 were divided into two groups according to the sequence of admission: control group (n = 30) received routine general treatment, and observation group (n = 30) on the basis of conventional comprehensive treatment with entecavir treatment, the clinical efficacy of the two groups were compared. Results: The 1-year survival rate of the observation group was 76.67%, which was significantly higher than that of the control group (46.67%, P <0.05). The ALB in the observation group was significantly higher than that in the control group (P <0.05) After treatment, ALT and TBIL in both groups were significantly decreased, and the observation group was significantly lower than the control group (P <0.05). Conclusion: Entecavir adjuvant treatment of hepatitis B liver failure can improve the survival rate of patients, improve or maintain the patient’s liver function, and fewer side effects, is a safe and reliable drug, worthy of clinical promotion.